论文部分内容阅读
随着发病率逐年增加,肥胖已成为全球公共健康问题。它不仅是一种多因素的慢性代谢性疾病,也是2型糖尿病、冠心病、高脂血症、肿瘤等多种疾病的危险因素。肥胖的发病机制复杂,与遗传、环境、氧化应激、肠道菌群及胰岛素抵抗密切相关。诊治肥胖,刻不容缓。胰高血糖素样肽-1(GLP-1)类似物是一种新型减重药物,既可保护B细胞功能、改善胰岛素抵抗,也可增加饱腹感、延缓胃排空、减少脂肪堆积,达到减肥目的。本文就肥胖发病现状、发病机制及GLP-1类似物对减重的影响进行综述。
As the incidence increases year by year, obesity has become a global public health problem. It is not only a multi-factor chronic metabolic disease, but also a type of diabetes, coronary heart disease, hyperlipidemia, cancer and other diseases risk factors. The pathogenesis of obesity is complex and closely related to genetics, environment, oxidative stress, gut flora and insulin resistance. Diagnosis and treatment of obesity, without delay. Glucagon-like peptide-1 (GLP-1) analog is a new type of weight loss drug that can protect B cell function, improve insulin resistance, increase satiety, delay gastric emptying, reduce fat accumulation, To lose weight purpose. This article reviews the current status of obesity, its pathogenesis, and the effects of GLP-1 analogues on weight loss.